Parikh, A. R., Overman, M. J., Chen, C. T., Elez, E., Wyrwicz, L., Cremolini, C., Taieb, J., Yuan, Y., Muro, K., Berz, D., Yin, M., Eckert, K. A., Paranthaman, N., Fakih, M. (2026). A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3682